| Cash Flow | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Net earnings | 38,185 | 91,078 | 68,490 | 33,600 |
| Depreciation and amortization | 24,340 | 82,792 | 55,221 | 28,137 |
| Costs recognized on sale of acquired inventory | - | 554 | 373 | 188 |
| Deferred income taxes | 5,275 | -18,825 | -13,417 | -5,340 |
| Stock-based compensation expense | 11,682 | 36,283 | 24,892 | 10,184 |
| Fair value adjustment to contingent consideration payable | - | 0 | 0 | - |
| Fair value adjustment on available-for-sale investments | - | 0 | 0 | - |
| (gain) loss on equity method investment | 294 | -169 | 420 | 374 |
| Asset impairment restructuring | - | 9,961 | 9,841 | 6,039 |
| (gain) loss on investments | 2,054 | - | - | - |
| Leases, net | -912 | 502 | 492 | 445 |
| Impairment (recovery) of assets held-for-sale | - | -3,655 | 0 | - |
| Recovery of assets held-for-sale | 6,789 | - | - | - |
| Other operating activity | 1,001 | 527 | 305 | 747 |
| Trade accounts and other receivables, net | -22,392 | -5,271 | -20,940 | -21,563 |
| Inventories | 14,002 | 11,540 | 11,713 | 2,805 |
| Prepaid expenses | -380 | 7,217 | 405 | 3,158 |
| Trade accounts payable, accrued expenses, contract liabilities, and other | -2,115 | -639 | -29 | -10,911 |
| Salaries, wages and related accruals | -22,101 | 12,006 | 3,882 | -8,246 |
| Income taxes payable | -27,403 | -7,912 | -10,217 | -6,180 |
| Net cash provided by (used in) operating activities | 27,585 | 189,355 | 148,235 | 63,889 |
| Proceeds from sale of available-for-sale investments | - | 1,085 | 1,085 | 1,085 |
| Purchases of available-for-sale investments | - | 0 | 0 | - |
| Additions to property and equipment | 5,363 | 26,116 | 15,993 | 9,172 |
| Acquisitions, net of cash acquired | - | 0 | 0 | - |
| Distributions from wilson wolf | 1,351 | 2,653 | 1,403 | 1,403 |
| Investment in spear bio | - | 15,000 | 15,000 | 15,000 |
| Proceeds from sale of assets held-for-sale | 4,617 | 1,789 | 1,789 | - |
| Net cash provided by (used in) investing activities | 605 | -35,589 | -26,716 | -21,684 |
| Cash dividends | 12,444 | 38,004 | 25,424 | 12,688 |
| Proceeds from stock option exercises | 23,495 | 45,513 | 30,641 | 25,101 |
| Repurchases of common stock | 24 | 175,674 | 75,628 | - |
| Borrowings under line-of-credit agreement | - | 38,000 | 0 | - |
| Repayments of long-term debt | 46,000 | 27,000 | 19,000 | 19,000 |
| Taxes paid on rsus and net share settlements | 9,231 | 6,288 | 5,997 | 4,984 |
| Net cash provided by (used in) financing activities | -44,204 | -163,453 | -95,408 | -11,571 |
| Effect of exchange rate changes on cash and cash equivalents | -1,210 | -1,434 | -353 | 5,115 |
| Net change in cash and cash equivalents | -17,224 | -11,121 | 25,758 | 35,749 |
| Cash and cash equivalents at beginning of period | 162,186 | 151,791 | 151,791 | 151,791 |
| Cash and cash equivalents at end of period | 144,962 | 140,670 | 177,549 | 187,540 |
BIO-TECHNE Corp (TECH)
BIO-TECHNE Corp (TECH)